Ocera Therapeutics Inc (NASDAQ:OCRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, AnalystRatingsNetwork.com reports. According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. […]
